N-domain ACE inhibitor

N-domain ACE inhibitor is a preclinical small-molecule program being developed by AngioDesign for the treatment of fibrosis. Unlike conventional ACE inhibitors that non-selectively inhibit both the N- and C-domains of the angiotensin-converting enzyme (ACE), this candidate is designed to selectively target the N-domain. The N-domain is primarily responsible for the hydrolysis of N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), a peptide with potent anti-fibrotic and anti-inflammatory properties. By selectively inhibiting the N-domain, the drug aims to increase endogenous levels of Ac-SDKP, thereby mitigating fibrotic progression in organs such as the heart, kidneys, and lungs without the blood-pressure-lowering effects typically associated with C-domain inhibition.

Other names

ACE N-domain inhibitorsmall-molecule ACE N-domain inhibitor